Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Pain Management Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

The Burden of Glaucoma: How Noncompliance Impacts Patients and Doctors

By: Kristopher A. May, OD, FAAO; Leslie O’Dell, OD, FAAO; Deborah Ristvedt, DO; Justin Schweitzer, OD, FAAO

Webinar Credits: .5

In this episode, faculty discuss the prevalence of glaucoma and how compliant patients are with their drop therapies. Faculty discuss why patients have difficulties with drops and how they impact their quality of life.

Expiration Date: Friday, December 30, 2022
Release Date: March 23, 2021

This course features bonus case material. View it here

Learning Objectives

Review the impact of patient compliance on conventional glaucoma treatment outcomes

Identify the importance of earlier intervention with the glaucoma patient, regardless of disease severity levels

Accreditation and Designation Statement

     Sponsored by:           
Evolve is an approved COPE Administrator.
This course is COPE approved for .5 hours of CE credit for optometrists.
COPE Course ID: 71825-GL
COPE Activity ID: 121417

Faculty and Disclosures

Christopher May, OD
Moderator

Coldwater Vision Center

Coldwater, MS

Deborah Ristvedt, DO

Vance Thompson Vision

Alexandria, MN

Leslie O’Dell, OD

Clinical Director of Medical Optometry America

York, PA

Justin Schweitzer, OD

Vance Thompson Vision

Sioux Falls, SD

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Kristopher May, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, and Sight Sciences. Speaker’s Bureau: Alcon, Bausch + Lomb, and Sight Sciences.

Leslie O’Dell, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie and Sight Sciences.

Deborah Ristvedt, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Glaukos, and Sight Sciences.  Grant/Research Support: Allergan.  Speaker’s Bureau: Alcon, and Glaukos.

Justin Schweitzer, OD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Dompe, EyePoint, Horizon, Ocular Therapeutix, and Reichert.  Grant/Research Support: Glaukos. Speaker’s Bureau: Aerie, Alcon, Allergan, Bausch + Lomb, Glaukos, Quidel, Sight Sciences, and Sun Pharmaceuticals. Share/Stockholder: Equinox.

The Evolve Medical Education or The Fundingsland Group staff and planners have no financial relationships with commercial interests.

 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group or Sight Sciences.

Pretest

Video Resources

Next

Test

Instructions

Step 1 of 2

  • AgreeNeutralDisagree
    Review the impact of patient compliance on conventional glaucoma treatment outcomes
    Identify the importance of earlier intervention with the glaucoma patient, regardless of disease severity levels
Back